Malaria Vaccine Averts One in Eight Child Deaths, Study Confirms

For the first time, a large real-world evaluation has confirmed what trials had suggested: malaria vaccines save children's lives at scale. On 8 May 2026, the World Health Organization announced new evidence, published in The Lancet, showing that the RTS,S malaria vaccine averted roughly one in eight deaths among children eligible to receive it in Ghana, Kenya and Malawi over a four-year period.

The findings come from the Malaria Vaccine Implementation Programme, which introduced RTS,S in those three countries between 2019 and 2023. Malaria remains a major killer of young children — an estimated 438,000 African children died from the disease in 2024 — so a vaccine that meaningfully cuts child mortality is a profound addition to existing tools such as bednets and antimalarial medicines. The evaluation also found no negative effect on the uptake of other childhood vaccines or on the use of other malaria-prevention measures.

"This is very solid evidence of the potential for malaria vaccines to change the trajectory of child mortality in Africa," said Dr Kate O'Brien, WHO's Director of Immunization. Dr Daniel Ngamije Madandi, WHO's Director of the Malaria Department, noted that malaria vaccination "strengthens the response and increases access to malaria prevention" when integrated with other interventions. Twenty-five endemic African countries are now offering malaria vaccines, targeting more than 10 million children a year.

Important caveats remain. The vaccine is one layer of protection, not a stand-alone solution, and its benefit is greatest when combined with bednets, prompt diagnosis and treatment. WHO stressed that supply is now sufficient but that funding constraints threaten to slow the rollout, even as more countries seek to introduce the vaccine. Still, the message is hopeful and concrete: after decades of effort, the world finally has malaria vaccines proven in real conditions to keep large numbers of African children alive.